The SurVeil™ drug-coated balloon: a next-generation technology
Previous clinical trials have demonstrated that drug-coated balloons (DCBs) are effective in treating peripheral artery disease.1-3 However, for a DCB to provide optimal performance, the device must consistently deliver the correct drug dosage at the treatment site and apply the drug uniformly to the wall of the artery, while minimizing the unintended release of the drug into the bloodstream during the procedure. This presents a significant challenge to medical device manufacturers.
The SurVeil™ DCB is made using an innovative balloon coating technology which limits release of the drug until it’s needed. However, when the drug is administered to the treatment area, pre-clinical testing has shown a more evenly distributed application of the drug.4
The SurVeil DCB also includes the Surmodics Serene™ coating on the catheter shaft to reduce friction, making it easier to guide the catheter to the treatment site.
The SurVeil™ drug-coated balloon
References:
Schneider PA, Laird JR, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11(1):e005891.
Tepe G, Laird JR, Schneider PA, Brodmann M, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015 Feb 3;131(5):495-502.
Al-Bawardy RF, Waldo SW, Rosenfield K. Advances in Percutaneous Therapies for Peripheral Artery Disease: Drug-Coated Balloons. Curr Cardiol Rep. 2017 Aug 24;19(10):99.
Surmodics data on file.
